蛋白激酶CI的表达与胰腺癌的相关性分析

doi:10.19739/j.cnki.issn1001-9510.2021.03.001

Abstract
Figure/Table
References
Related Citation (3)

Download: PDF (2936 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the expression of PRKCI in pancreatic cancer, to clarify its role in the prognosis of pancreatic cancer, and to analyze the relationship between PRKCI and immune cell infiltration in tumor microenvironment.Methods Oncomine, GEPIA, HPA and CCLE databases were used to analyze the expression of PRKCI in pancreatic cancer tissues and cell lines; GEPIA was used to analyze the relationship between PRKCI expression and the prognosis of pancreatic cancer patients; String database was used to analyze the protein interacting with PRKCI; TIMER was used to detect the correlation between PRKCI expression and tumor purity and immune cell infiltration.Results The expression of PRKCI in pancreatic cancer tissues was significantly higher than that in normal pancreatic tissues. PRKCI was also highly expressed in pancreatic cancer cell lines. The overall survival and disease-free survival of pancreatic cancer patients with high PRKCI expression were significantly lower than those with low PRKCI expression (P<0.01) and the expression of PRKCI was significantly correlated with the stage of pancreatic cancer. Proteins interacting with PRKCI include CDC42, NUMB, SQSTM1 and so on, which are mainly involved in inflammatory reaction and protein phosphorylation. The expression of PRKCI was negatively correlated with CD4⁺ T cells, PD-L1 and CTLA-4 in pancreatic cancer.Conclusion PRKCI is highly expressed in pancreatic cancer. The expression of PRKCI is significantly correlated with the prognosis and immune cells. PRKCI may act as a potential therapeutic target for pancreatic cancer.

Key words： PRKCI expression immune infiltrate database

Received: 07 January 2020

PACS:

R735.9

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	RAN Deyuan
	YU Yunliang

Cite this article:

RAN Deyuan,YU Yunliang. Relationship between the expression of PRKCI and pancreatic cancer[J]. 滨州医学院学报, 2021, 44(3): 161-166.

URL:

http://manu58.magtech.com.cn/Jwk_bzyxy/EN/10.19739/j.cnki.issn1001-9510.2021.03.001 OR http://manu58.magtech.com.cn/Jwk_bzyxy/EN/Y2021/V44/I3/161

[1] 韩连强,谭杨,杨奇,等.胰腺癌治疗进展[J].中华消化病与影像杂志(电子版),2019,9(2):49-54.
[2] FIELDS A P, ALI S A, MURRAY N R. Oncogenic PKCι decides tumor-initiating cell fate [J]. Cell Cycle, 2016,15(18):2383-2384.
[3] 王蕾,姜寰宇,宋凯镔,等.miR-219调控PRKCI表达在舌鳞状细胞癌中作用和机制[J].实用肿瘤学杂志,2018,32(6):510-514.
[4] QI S X, SUN H, LIU H, et al. Role and mechanism of circ-PRKCI in hepatocellular carcinoma [J]. World Journal of Gastroenterology, 2019, 25(16):1964-1974.
[5] HASHIMOTO I, SAKAMAKI K, OUE N, et al. Clinical Significance of PRKCI Gene Expression in Cancerous Tissue in Patients With Gastric Cancer [J]. Anticancer research, 2019, 39(10):5715-5720.
[6] TSANG T Y, WEI W, ITAMOCHI H, et al. Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target [J]. Oncotarget, 2017, 8(57):96482-96495.
[7] ZHOU L, LI Y, JIANG W, et al. Down-regulation of circ-PRKCI inhibits cell migration and proliferation in Hirschsprung disease by suppressing the expression of miR-1324 target PLCB1 published correction appears in Cell Cycle [J]. Cell Cycle, 2018, 17(9):1092-1101.
[8] SARKAR S, BRISTOW C A, DEY P, et al. PRKCI promotes immune suppression in ovarian cancer [J]. Genes Dev, 2017, 31(11):1109-1121.
[9] LI Q, GU C, ZHU Y, et al. Two novel PRKCI polymorphisms and prostate cancer risk in an Eastern Chinese Han population [J]. Molecular Carcinogenesis, 2015, 54(8):632-641.
[10] QI S X, SUN H, LIU H, et al. Role and mechanism of circ-PRKCI in hepatocellular carcinoma [J]. World Journal of Gastroenterology, 2019, 25(16):1964-1974.
[11] TSANG T Y, WEI W, ITAMOCHI H, et al. Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target [J]. Oncotarget, 2017, 8(57):96482-96495.
[12] LIU Y, YIN N, WANG X, et al. Chromosome 3q26 Gain Is an Early Event Driving Coordinated Overexpression of the PRKCI, SOX2, and ECT2 Oncogenes in Lung Squamous Cell Carcinoma [J]. Cell Reports, 2020, 30(3):771-782.